BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 12139740)

  • 21. Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 overexpression in plasma cell malignancies.
    Nakazawa N; Nishida K; Tamura A; Kobayashi M; Iwai T; Horiike S; Nishigaki H; Otsuki T; Tomiyama Y; Fujii H; Kashima K; Taniwaki M
    Cancer Genet Cytogenet; 2000 Mar; 117(2):89-96. PubMed ID: 10704676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of ID-1 as a potential target gene of MMSET in multiple myeloma.
    Hudlebusch HR; Theilgaard-Mönch K; Lodahl M; Johnsen HE; Rasmussen T
    Br J Haematol; 2005 Sep; 130(5):700-8. PubMed ID: 16115125
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
    Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
    Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.
    Lauring J; Abukhdeir AM; Konishi H; Garay JP; Gustin JP; Wang Q; Arceci RJ; Matsui W; Park BH
    Blood; 2008 Jan; 111(2):856-64. PubMed ID: 17942756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma.
    Fracchiolla NS; Luminari S; Baldini L; Lombardi L; Maiolo AT; Neri A
    Blood; 1998 Oct; 92(8):2987-9. PubMed ID: 9763594
    [No Abstract]   [Full Text] [Related]  

  • 26. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene.
    Richelda R; Ronchetti D; Baldini L; Cro L; Viggiano L; Marzella R; Rocchi M; Otsuki T; Lombardi L; Maiolo AT; Neri A
    Blood; 1997 Nov; 90(10):4062-70. PubMed ID: 9354676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts.
    Malgeri U; Baldini L; Perfetti V; Fabris S; Vignarelli MC; Colombo G; Lotti V; Compasso S; Bogni S; Lombardi L; Maiolo AT; Neri A
    Cancer Res; 2000 Aug; 60(15):4058-61. PubMed ID: 10945609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis.
    Perfetti V; Coluccia AM; Intini D; Malgeri U; Vignarelli MC; Casarini S; Merlini G; Neri A
    Am J Pathol; 2001 May; 158(5):1599-603. PubMed ID: 11337357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma.
    Zhu L; Somlo G; Zhou B; Shao J; Bedell V; Slovak ML; Liu X; Luo J; Yen Y
    Mol Cancer Ther; 2005 May; 4(5):787-98. PubMed ID: 15897243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a novel IGH-MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16.3;q32) chromosomal translocation.
    Intini D; Fabris S; Storlazzi T; Otsuki T; Ciceri G; Verdelli D; Lombardi L; Rocchi M; Neri A
    Br J Haematol; 2004 Aug; 126(3):437-9. PubMed ID: 15257719
    [No Abstract]   [Full Text] [Related]  

  • 31. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.
    Martinez-Garcia E; Popovic R; Min DJ; Sweet SM; Thomas PM; Zamdborg L; Heffner A; Will C; Lamy L; Staudt LM; Levens DL; Kelleher NL; Licht JD
    Blood; 2011 Jan; 117(1):211-20. PubMed ID: 20974671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FGFR3 preferentially colocalizes with IGH in the interphase nucleus of multiple myeloma patient B-cells when FGFR3 is located outside of CT4.
    Martin LD; Harizanova J; Mai S; Belch AR; Pilarski LM
    Genes Chromosomes Cancer; 2016 Dec; 55(12):962-974. PubMed ID: 27509849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.
    Grand EK; Chase AJ; Heath C; Rahemtulla A; Cross NC
    Leukemia; 2004 May; 18(5):962-6. PubMed ID: 15029211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma.
    Chang H; Stewart AK; Qi XY; Li ZH; Yi QL; Trudel S
    Blood; 2005 Jul; 106(1):353-5. PubMed ID: 15761022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel mutation involving the carboxy terminal region of the FGFR3 gene in a multiple myeloma patient with t(4;14).
    Intini D; Baldini L; Lombardi L; Neri A
    Leukemia; 2002 Jun; 16(6):1201-2. PubMed ID: 12040455
    [No Abstract]   [Full Text] [Related]  

  • 36. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
    Chesi M; Brents LA; Ely SA; Bais C; Robbiani DF; Mesri EA; Kuehl WM; Bergsagel PL
    Blood; 2001 Feb; 97(3):729-36. PubMed ID: 11157491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma.
    Quintero-Rivera F; El-Sabbagh Badr R; Rao PN
    Cancer Genet Cytogenet; 2009 Nov; 195(1):92-3. PubMed ID: 19837276
    [No Abstract]   [Full Text] [Related]  

  • 38. Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes.
    Sáez B; Martín-Subero JI; Lahortiga I; Largo C; Larrayoz MJ; Odero MD; Prosper F; Cigudosa JC; Siebert R; Calasanz MJ
    Cancer Genet Cytogenet; 2007 May; 175(1):65-8. PubMed ID: 17498561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGFR3 dysregulation and clinical outcome in myeloma.
    Rasmussen T; Hudlebusch HR; Knudsen LM; Johnsen HE
    Br J Haematol; 2003 Jan; 120(1):166. PubMed ID: 12492593
    [No Abstract]   [Full Text] [Related]  

  • 40. Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor.
    Qian S; Somlo G; Zhou B; Zhu L; Mi S; Mo X; Cheung EM; Qiu W; Lin RJ; Rossi J; Holtz M; Chu P; Yen Y
    Oligonucleotides; 2005; 15(1):1-11. PubMed ID: 15788896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.